The article reports that the Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report assessing the comparative clinical effectiveness and value of mavacamten for the treatment of hypertrophic cardiomyopathy. Topics include considered that ICER's President Steven D. Pearson present the initial findings of this draft report.
Processing Request
No Comments.